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Incidence and Risk Factors of Steroid-induced Diabetes  
in Patients with Respiratory Disease
Glucocorticoids are effective for treating several respiratory diseases. However, they can 
cause hyperglycemia. This study determined the incidence and risk factors of steroid-
induced diabetes mellitus (S-DM) in patients treated with glucocorticoid for respiratory 
diseases. A retrospective study examined patients with respiratory diseases treated with a 
prednisolone-equivalent glucocorticoid dose exceeding 20 mg/day for at least 4 weeks 
between January 2003 and December 2008. Patients whose initial random glucose level 
exceeded 200 mg/dL or who had pre-existing diabetes were excluded. S-DM was defined 
as a fasting glucose concentration exceeding 126 mg/dL or a random glucose concentration 
exceeding 200 mg/dL at least twice after beginning steroid treatment. A total of 231 
patients with respiratory diseases met the inclusion criteria. Their median age was 55 yr, 
and 139 were female. The median cumulative prednisolone-equivalent glucocorticoid dose 
was 4,965 mg, and the median duration of steroid treatment was 193 days. S-DM was 
diagnosed in 34 (14.7%) of 231 patients. Multivariate logistic regression identified older 
age (odds ratio 1.05, 95% confidence interval 1.02-1.09) as a risk factor for S-DM. S-DM 
is frequent among patients with respiratory diseases treated with glucocorticoid. Clinicians 
should be aware of the possibility of S-DM, especially among elderly patients.
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Respiratory Diseases
INTRODUCTION
Since the introduction of glucocorticoids in the 1950s, they have 
played a pivotal role in the treatment of various inflammatory 
diseases, including respiratory diseases. As they decrease inflam-
mation and minimize tissue damage (1), glucocorticoids have 
been used widely to treat idiopathic interstitial pneumonia, 
chronic obstructive pulmonary disorders, endobronchial tu-
berculosis, sarcoidosis, hypersensitivity pneumonitis, and other 
respiratory diseases.
  However, glucocorticoids have various adverse effects. They 
can cause glaucoma, fluid retention, increased blood pressure, 
increased blood sugar, menstrual irregularities, weight gain, 
stomach pain, insomnia, and infection. Impaired glucose me-
tabolism is one of the commonest adverse effects. Glucocorti-
coids not only exacerbate hyperglycemia in patients with known 
diabetes mellitus (DM), but also cause DM in patients without 
documented hyperglycemia before the initiation of glucocorti-
coid therapy (2). The hyperglycemic condition is transient in 
many cases, but some patients may develop polydipsia, polyuria, 
and repeated infections. Especially in the elderly, there is a risk 
of precipitating hyperglycemic hyperosmolar states, including 
coma. In the long-term, the overall burden of repeated increas-
es in blood glucose may increase cardiovascular risk (3, 4) and 
the risk of microvascular complications (5).
  This study examined the incidence and clinical risk factors of 
steroid-induced DM in patients treated with glucocorticoid ther-
apy for various respiratory diseases.
 
MATERIALS AND METHODS
Patients
We included adult patients (age > 20 yr) with respiratory diseases 
who were newly started on glucocorticoids from January 2003 
through December 2008 at three hospitals affiliated with Seoul 
National University, Korea: Seoul National University Hospital, 
Seoul National University Bundang Hospital, and Seoul Nation-
al University Boramae Hospital. The respiratory diseases treat-Kim SY, et al.  •  Steroid-induced Diabetes 
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ed with glucocorticoid included idiopathic interstitial pneumo-
nia, endobronchial tuberculosis, sarcoidosis, and hypersensi-
tivity pneumonitis. Patients with asthma and chronic obstruc-
tive pulmonary disease (COPD) were not included, not only 
because they frequently used inhaled steroid, but also because 
their use of systemic steroid was usually short term.
  Patients with respiratory diseases treated with systemic gluco-
corticoid exceeding a prednisolone-equivalent dose of 20 mg/
day for at least for 4 weeks were included in the analysis. Patients 
with pre-existing diabetes or an initial random glucose level ex-
ceeding 200 mg/dL before initiating steroid therapy were exclud-
ed. We also excluded patients who were treated with steroid for 
other than lung diseases, such as malignancy, rheumatoid ar-
thritis, transplantation, and nephrotic syndrome.
  The demographic characteristics, clinical findings, and labo-
ratory results were obtained from a retrospective review of the 
medical records. In addition, detailed information on the use of 
glucocorticoid (daily dose, duration of treatment, and cumula-
tive dose) was collected.
  Steroid-induced DM (S-DM) was defined as a fasting glucose 
concentration above 126 mg/dL or a random glucose concen-
tration exceeding 200 mg/dL at least twice after beginning ste-
roid treatment. 
Statistical analysis
The chi-squared test was used to compare categorical variables, 
and the t-test to compare continuous variables between patients 
with and without S-DM. The variables analyzed included age, 
sex, body mass index (BMI), underlying lung diseases, daily and 
cumulative dose of steroid, duration of treatment, and initial 
random serum glucose level. To identify predictors of S-DM, 
multiple logistic regression models were constructed that in-
cluded any variables with P < 0.10. Statistical significance was 
considered if P < 0.05. All statistical analyses were performed 
using SPSS
® (Version 12.0, Chicago, IL, USA).
Ethics statement
The study protocol was approved by the institutional review boards 
of the Seoul National University Hospital (H-0906-059-284), 
Seoul National University Bundang Hospital (B-1001-092-103), 
and Seoul National University Boramae Hospital (06-2010-4).
RESULTS
Incidence of steroid-induced diabetes
The analysis included 231 patients with respiratory diseases who 
started taking systemic glucocorticoid during the study period. 
Their median age was 55 yr (range 22–85 yr), and 139 were fe-
male (60.2%). The baseline clinical characteristics and labora-
tory findings of the study population are summarized in Table 
1. Respiratory diseases requiring glucocorticoid treatment in-
cluded idiopathic interstitial pneumonia (125 patients), endo-
Table 1. Baseline demographic and clinical characteristics of the patients with respiratory diseases treated with steroid
Characteristics All patients 
Patients with  
steroid-induced DM
Patients without  
steroid-induced DM
P value
Number of subjects 231 34  197 
Demographic characteristics
   Age, yr (median, range)
   Male sex (%)
   Body mass index (kg/m
2)
   Current or ex-smoker
   Pack-years
 
  55 (22-85)
  92 (39.8%)
23.2 ± 3.7
  80 (34.6%)
10.7 ± 20.2
 
  65 (50-81)
   18 (52.9%)
23.6 ± 3.2
   19 (55.9%)
23.1 ± 25.5
 
  53 (22-85)
  74 (37.6%)
22.9 ± 3.8
61 (31 %)
8.5 ± 18.4
 
< 0.001
0.09
0.53
0.005
0.004
Respiratory diseases requiring steroid treatment
   Idiopathic interstitial pneumonitis
   Endobronchial tuberculosis
   Sarcoidosis
   Hypersensitive pneumonitis
 
125 (54.1%)
  60 (26.0%)
  43 (18.6%)
  3 (1.3%)
 
   27 (79.4%)
   2 (5.9%)
     5 (14.7%)
0
 
  98 (49.7%)
  58 (29.4%)
  38 (19.3%)
  3 (1.5%)
 
0.001
0.004
0.53
> 0.99
Comorbidities
   Hypertension
   Hyperlipidemia
   Chronic kidney disease
   Chronic liver disease
   Malignancy
 
  35 (15.4%)
12 (5.3%)
11 (4.8%)
  3 (1.3%)
10 (4.4%)
 
     8 (25.0%)
     4 (12.5%)
   1 (3.0%)
0
   2 (6.5%)
 
  27 (13.8%)
  8 (4.1%) 
10 (5.1%)
  3 (1.5%)
  8 (4.1%)
 
0.12
0.07
> 0.99
> 0.99
0.63
Initial laboratory findings 
   Random glucose (mg/dL)
   Creatinine (mg/dL)
   Cholesterol (mg/dL)
 
  101 (59-198)
   0.9 (0.4-1.5)
  179 (88-331)
 
  108 (76-190)
   0.9 (0.6-1.4)
    186 (121-283)
 
  100 (59-198)
   0.9 (0.4-1.5)
  178 (88-331)
 
0.12
0.71
0.22
Use of glucocorticoid (median, range)
   Total dose* (mg)
   Daily dose (mg)
   Total duration (days)
 
      4,965 (560-32,585)
21.4 (6-64.4)
     193 (28-1,869)
 
      5,454 (940-23,590)
24.6 (7-58.9)
     168 (33-1,408)
 
      4,880 (560-32,585)
20.4 (6-64.4)
     198 (28-1,869)
 
0.60
0.25
0.91
*Equivalent dose of prednisolone.Kim SY, et al.  •  Steroid-induced Diabetes 
266   http://jkms.org DOI: 10.3346/jkms.2011.26.2.264
bronchial tuberculosis (60 patients), sarcoidosis (43 patients), 
and hypersensitivity pneumonitis (three patients).
  The median random glucose before initiating glucocorticoid 
in the 231 patients was 101 mg/dL (range 59–198 mg/dL). The 
median cumulative prednisolone-equivalent dose of glucocor-
ticoid was 4,965 mg (range 560-32,585 mg), and the median du-
ration of steroid treatment was 193 days (range 28-1,869 days). 
S-DM was diagnosed in 34 (14.7%) out of 231 patients.
Risk factors of steroid-induced diabetes
The patients who developed S-DM were older than the patients 
who did not (65 vs 53 yr, P < 0.001). In addition, idiopathic in-
terstitial pneumonitis was more common (79.4% vs 49.7%, P = 
0.001), and endobronchial tuberculosis was less common (5.9% 
vs 29.4%, P = 0.004) among patients with S-DM than among those 
without S-DM. However, neither the cumulative dose nor the 
duration of glucocorticoid use was associated with the develop-
ment of S-DM (Table 1).
  Multiple logistic regression analysis revealed that only older 
age (odds ratio [OR] 1.05, 95% confidence interval [CI] 1.02–1.09) 
was an independent risk factor for developing S-DM (Table 2).
Evolution of steroid-induced diabetes
The median time of onset of S-DM was 91.5 days (range 15-1,733 
days); 18 patients (52.9%) were diagnosed in the first 3 months, 
and five patients (14.5%) after 1 yr. Among the 23 patients fol-
lowed for longer than 6 months after the diagnosis of S-DM, 10 
were treated with oral hypoglycemic drugs and five with insu-
lin. The other eight patients were observed without treatment. 
Treatment for S-SM could be stopped after a median of 202 days 
(range 47-1,621 days) in seven of the 15 patients in whom hy-
poglycemic agents and insulin were initiated.
   
DISCUSSION
Glucocorticoids can cause hyperglycemia via insulin resistance, 
which augments hepatic gluconeogenesis and lowers glucose 
uptake by peripheral tissues such as muscle cells and adipocytes 
(2, 6). For these reasons, it is not uncommon to observe abnor-
mal glucose tolerance among patients receiving steroid thera-
Table 2. Predictors of steroid-induced DM (multivariable analysis)
Parameters Odds ratio
95% confidence 
interval
P value
Age* (yr) 1.05 (1.02-1.09) 0.006
Sex, Male 1.70 (0.48-5.99) 0.41
Smoking 1.36 (0.29-6.32) 0.70
Pack-years 1.02 (0.99-1.05) 0.22
Hyperlipidemia 2.12 (0.47-9.47) 0.33
Idiopathic interstitial pneumonias 1.19 (0.36-3.86) 0.78
Endobronchial tuberculosis 0.38 (0.06-2.31) 0.30
*(year X + 1 vs year X).
py. In the present study of 231 patients with respiratory diseases 
who received glucocorticoid, 34 (14.7%) of the patients experi-
enced S-DM. Given that the incidence of S-DM in other condi-
tions requiring glucocorticoids, such as connective tissue dis-
eases, was between 0.4% and 54% (7-11), the proportion of pa-
tients with respiratory disease treated with steroid who devel-
oped S-DM in our study is comparable. The wide variability may 
reflect different study populations, doses of glucocorticoid, du-
ration of follow-up, and different diagnostic criteria for S-DM.
  Proposed risk factors for S-DM included old age, high BMI, 
impaired glucose tolerance before therapy, cumulative dose, 
and long duration of steroid therapy. However, these results 
were not always consistent across studies (10-13). In our series 
of 231 patients treated with steroid for respiratory diseases, only 
old age was an independent risk factor for S-DM.
  Glucose tolerance declines progressively with age, resulting 
in a high incidence of type 2 diabetes and impaired glucose tol-
erance in the old population (14, 15). According to the Korean 
National Health and Nutrition Examination Survey (16), 45% of 
Koreans 65 yr and older meet the diagnostic criteria for type 2 
diabetes or impaired glucose tolerance. With aging, beta-cell 
function declines, and basal insulin secretion level decreases 
(17). In addition, the interaction of many factors associated with 
aging likely contributes to the altered glucose tolerance. These 
factors include obesity, decreased physical activity, medications, 
and coexisting illness (18). Considering the vulnerability of the 
aged population to glucose intolerance, the association of S-DM 
and age in our study can be understood.
  To appreciate our results correctly, we should consider the 
limitations of this study. The effects of glucocorticoid on glu-
cose metabolism are greater in the postprandial state than when 
fasting (10, 11, 19). In our study, however, we monitored fasting 
blood glucose rather than the postprandial plasma glucose lev-
el. In this context, our study could underestimate the incidence 
of S-DM.
  In conclusion, S-DM is frequent among patients with respi-
ratory diseases treated with glucocorticoid. Clinicians should 
be aware of the possibility of steroid-induced DM, especially 
among old patients.
 
REFERENCES
1. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-
inflammatory action and of immunosuppression by glucocorticoids: 
negative interference of activated glucocorticoid receptor with transcrip-
tion factors. J Neuroimmunol 2000; 109: 16-22.
2. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr 
Pract 2009; 15: 469-74.
3. The DECODE study group on behalf of the Europe an Diabetes Epide-
miology Group. Glucose tolerance and mortality: comparison of WHO 
and American Diabetic Association diagnostic criteria. Lancet 1999; 
354: 617-21.Kim SY, et al.  •  Steroid-induced Diabetes 
http://jkms.org   267 DOI: 10.3346/jkms.2011.26.2.264
4. Kim HB, Han KH, Chung JY, Lee BW, Kweon SH, Kim BI, Lee M, Lee SJ, 
Lee HS, Imm CW. Clinical study on coronary risk factors in NIDDM. 
Korean J Intern Med 1992; 43: 770-5.
5. The Diabetes Control and Complications Trial Research Group. The ef-
fect of intensive treatment of diabetes on the development and progres-
sion of long-term complications in insulin-dependent diabetes melli-
tus. N Engl J Med 1993; 329: 977-86.
6. Tryfon S, Papanas N. Corticosteroid-induced diabetes in patients with 
chronic obstructive pulmonary disease. Clin Pulm Med 2008; 15: 127-31.
7. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Post-
transplantation diabetes: a systematic review of the literature. Diabetes 
Care 2002; 25: 583-92.
8. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and manage-
ment of hyperglycaemia in patients with rheumatoid arthritis on corti-
costeroid therapy. Scott Med J 2004; 49: 139-41.
9. Smyllie HC, Connolly CK. Incidence of serious complications of cortico-
steroid therapy in respiratory disease. A retrospective survey of patients 
in the Brompton hospital. Thorax 1968; 23: 571-81.
10. Uzu T, Harada T, Sakaguchi M, Kanasaki M, Isshiki K, Araki S, Sugiomo-
to T, Koya D, Haneda M, Kashiwagi A, Yamauchi A. Glucocorticoid-in-
duced diabetes mellitus: prevalence and risk factors in primary renal 
diseases. Nephron Clin Pract 2007; 105: c54-7.
11. Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M. Steroid-induced 
diabetes mellitus and related risk factors in patients with neurologic 
diseases. Pharmacotherapy 2004; 24: 508-14.
12. Raúl Ariza-Andraca C, Barile-Fabris LA, Frati-Munari AC, Baltazár-
Montufar P. Risk factors for steroid diabetes in rheumatic patients. Arch 
Med Res 1998; 29: 259-62.
13. Arner P, Gunnarsson R, Blomdahl S, Groth CG. Some characteristics of 
steroid diabetes: a study in renal-transplant recipients receiving high-
dose corticosteroid therapy. Diabetes Care 1983; 6: 23-5.
14. Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Järvinen H, Ferrannini 
E. Independent influence of age on basal insulin secretion in nondiabetic 
humans. European Group for the Study of Insulin Resistance. J Clin En-
docrinol Metab 1999; 84: 863-8.
15. Kim SG, Yang SW, Choi SI, Park SH, Lee KR, Park JH, Jang AS, Seo JP, 
Lee S, Nam HS, Sun MH, Shin MG, Chung DJ, Chung MY. Prevalence of 
diabetes mellitus in the elderly of Namwon county, South Korea. Kore-
an J Med 2001; 60: 555-66. 
16. Korean National Health and Nutrition Examination Survey. 2008. Avail-
able at http://knhanes.cdc.go.kr [accessed on 13 Jul 2010].  
17. Thearle M, Brillantes AM. Unique characteristics of the geriatric diabetic 
population and the role for therapeutic strategies that enhance glucagon-
like peptide-1 activity. Curr Opin Clin Nutr Metab Care 2005; 8: 9-16.
18. Chang AM, Halter JB. Aging and insulin secretion. Am J Physiol Endo-
crinol Metab 2003; 284: E7-12.
19  Hoogwerf B, Danese RD. Drug selection and the management of corti-
costeroid-related diabetes mellitus. Rheum Dis Clin North Am 1999; 25: 
489-505.
AUTHOR SUMMARY
Incidence and Risk Factors of Steroid-induced Diabetes in Patients with Respiratory 
Disease
Seo Yun Kim, Chul-Gyu Yoo, Chun Taeg Lee, Hee Soon Chung, Young Whan Kim, Sung Koo Han, Young-Soo Shim, and Jae-Joon Yim
We investigated the incidence and risk factors of steroid-induced diabetes mellitus (S-DM) in patients treated with glucocorticoid 
for respiratory diseases. A retrospective study examined patients with respiratory diseases treated with a prednisolone-equivalent 
glucocorticoid dose exceeding 20 mg/day for at least 4 weeks. S-DM was defined as a fasting glucose concentration exceeding 
126 mg/dL or a random glucose concentration exceeding 200 mg/dL at least twice after beginning steroid treatment. A total of 
231 patients met the inclusion criteria. The median cumulative prednisolone-equivalent glucocorticoid dose was 4,965 mg, and 
the median duration of steroid treatment was 193 days. S-DM was diagnosed in 34 (14.7%) of 231 patients. Older age was 
identified as a risk factor for S-DM. In conclusion, clinicians should be aware of the possibility of S-DM for patients with 
respiratory diseases, especially among patients. 